« Return to News | CROs/Service Providers

Quintiles invests $1 million in Prana Biotechnology

Tuesday, July 5, 2011 12:21 PM

Quintiles is raising its stake in Prana Biotechnology, an Australian company focused on Alzheimer’s disease and other major age-related neurodegenerative disorders, by acquiring $1 million worth of new Prana shares, according to PharmaTimes.

The new funding will be used to support Prana’s strategy to accelerate clinical development of its lead compound PBT2, in phase II trials for Alzheimer’s disease.

In April, Prana said it was widening the target indications for PBT2 to include Huntington’s disease, which “should enable Prana to target market approval for PBT2 several years sooner than previously planned and at considerably less cost.”

A six-month phase II placebo-controlled trial of the compound in 100 mild Huntington’s disease patients is scheduled to start in the fourth quarter of 2011. In the third quarter, Prana plans to initiate a 12-month phase II brain imaging study of PBT2 in 40 mild Alzheimer’s Disease patients.

Prana said in June 2010 Quintiles had agreed to acquire more than 7 million new ordinary shares in Prana.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.